Cargando…

Receptor Specificity Engineering of TNF Superfamily Ligands

The tumor necrosis factor (TNF) ligand family has nine ligands that show promiscuity in binding multiple receptors. As different receptors transduce into diverse pathways, the study on the functional role of natural ligands is very complex. In this review, we discuss the TNF ligands engineering for...

Descripción completa

Detalles Bibliográficos
Autores principales: Suo, Fengzhi, Zhou, Xinyu, Setroikromo, Rita, Quax, Wim J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8781899/
https://www.ncbi.nlm.nih.gov/pubmed/35057080
http://dx.doi.org/10.3390/pharmaceutics14010181
_version_ 1784638191165243392
author Suo, Fengzhi
Zhou, Xinyu
Setroikromo, Rita
Quax, Wim J.
author_facet Suo, Fengzhi
Zhou, Xinyu
Setroikromo, Rita
Quax, Wim J.
author_sort Suo, Fengzhi
collection PubMed
description The tumor necrosis factor (TNF) ligand family has nine ligands that show promiscuity in binding multiple receptors. As different receptors transduce into diverse pathways, the study on the functional role of natural ligands is very complex. In this review, we discuss the TNF ligands engineering for receptor specificity and summarize the performance of the ligand variants in vivo and in vitro. Those variants have an increased binding affinity to specific receptors to enhance the cell signal conduction and have reduced side effects due to a lowered binding to untargeted receptors. Refining receptor specificity is a promising research strategy for improving the application of multi-receptor ligands. Further, the settled variants also provide experimental guidance for engineering receptor specificity on other proteins with multiple receptors.
format Online
Article
Text
id pubmed-8781899
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87818992022-01-22 Receptor Specificity Engineering of TNF Superfamily Ligands Suo, Fengzhi Zhou, Xinyu Setroikromo, Rita Quax, Wim J. Pharmaceutics Review The tumor necrosis factor (TNF) ligand family has nine ligands that show promiscuity in binding multiple receptors. As different receptors transduce into diverse pathways, the study on the functional role of natural ligands is very complex. In this review, we discuss the TNF ligands engineering for receptor specificity and summarize the performance of the ligand variants in vivo and in vitro. Those variants have an increased binding affinity to specific receptors to enhance the cell signal conduction and have reduced side effects due to a lowered binding to untargeted receptors. Refining receptor specificity is a promising research strategy for improving the application of multi-receptor ligands. Further, the settled variants also provide experimental guidance for engineering receptor specificity on other proteins with multiple receptors. MDPI 2022-01-13 /pmc/articles/PMC8781899/ /pubmed/35057080 http://dx.doi.org/10.3390/pharmaceutics14010181 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Suo, Fengzhi
Zhou, Xinyu
Setroikromo, Rita
Quax, Wim J.
Receptor Specificity Engineering of TNF Superfamily Ligands
title Receptor Specificity Engineering of TNF Superfamily Ligands
title_full Receptor Specificity Engineering of TNF Superfamily Ligands
title_fullStr Receptor Specificity Engineering of TNF Superfamily Ligands
title_full_unstemmed Receptor Specificity Engineering of TNF Superfamily Ligands
title_short Receptor Specificity Engineering of TNF Superfamily Ligands
title_sort receptor specificity engineering of tnf superfamily ligands
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8781899/
https://www.ncbi.nlm.nih.gov/pubmed/35057080
http://dx.doi.org/10.3390/pharmaceutics14010181
work_keys_str_mv AT suofengzhi receptorspecificityengineeringoftnfsuperfamilyligands
AT zhouxinyu receptorspecificityengineeringoftnfsuperfamilyligands
AT setroikromorita receptorspecificityengineeringoftnfsuperfamilyligands
AT quaxwimj receptorspecificityengineeringoftnfsuperfamilyligands